IL1B and pulmonary fibrosis: MSC therapy inhibits the progression of BLM‐induced pulmonary fibrosis by altering proinflammatory cytokine tumor necrosis factor‐α and IL‐1β [53, 54] and by reducing the infiltration of inflammatory cells, such as neutrophils and lymphocytes [50], in a paracrine way.